Hyperkalemia Management

Clinical Manifestations

The American Heart Association notes that hyperkalemia is often asymptomatic or presents with nonspecific symptoms, and the first indicator may be peaked T waves on ECG rather than clinical symptoms, with ECG changes progressing in a characteristic pattern as potassium rises 1
The American College of Cardiology recommends considering ECG findings, including peaked T waves, flattened or absent P waves, prolonged PR interval, widened QRS complex, and deepened S waves, as critical findings in hyperkalemia diagnosis, although ECG findings are highly variable and not as sensitive as laboratory testing in predicting hyperkalemia or its complications 1, 2
Neuromuscular symptoms of hyperkalemia include flaccid paralysis, paresthesias, depressed deep tendon reflexes, respiratory difficulties, and muscle weakness, particularly in severe cases 1, 2

The European Society of Cardiology classifies hyperkalemia severity as mild (>5.0 to <5.5 mEq/L), moderate (5.5 to 6.0 mEq/L), and severe (>6.0 mEq/L or >6.5 mEq/L by some definitions) 1, 3

The American Heart Association recommends immediate multi-pronged treatment for life-threatening hyperkalemia (>6.5 mEq/L or ECG changes), including calcium for membrane stabilization, agents to shift potassium intracellularly, and measures to remove potassium from the body 1, 2
The European Heart Journal suggests using calcium chloride 10% (5-10 mL or 500-1000 mg IV over 2-5 minutes) or calcium gluconate 10% (15-30 mL IV over 2-5 minutes) to stabilize cardiac membranes, which does not lower potassium levels but protects against arrhythmias 1, 2
Insulin plus glucose is a reliable agent for shifting potassium into cells, with a recommended dose of 25 g glucose (50 mL of D50) with 10 U regular insulin IV over 15-30 minutes 1
The Mayo Clinic recommends using loop diuretics (e.g., furosemide 40-80 mg IV) and hemodialysis as effective methods for removing potassium from the body 1, 2

The American College of Cardiology advises against discontinuing RAAS inhibitors after a single elevated potassium measurement, as this offsets survival benefits, and instead recommends modifying the dose or using other treatment options such as loop or thiazide diuretics, potassium binders, or dietary potassium restriction 2, 3
The European Heart Journal suggests using newer potassium binders (patiromer or sodium zirconium cyclosilicate) for ongoing maintenance, and fludrocortisone in cases of aldosterone deficiency, although this carries a risk of fluid retention and hypertension 2, 4
High-risk populations requiring close monitoring include those with advanced chronic kidney disease, chronic heart failure, diabetes, elderly patients, and those on spironolactone or other RAAS inhibitors, with up to 73% risk of hyperkalemia in advanced chronic kidney disease and up to 40% risk in chronic heart failure 3